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Background. e number of patients receiving direct oral anticoagulants (DOACs) is increasing, however, this treatment is associated 
with the risk of bleeding. More than 10 percent of patients on DOACs have to interrupt their anticoagulation for an invasive procedure 
every year. For this reason, the correct management of DOACs in the perioperative setting is mandatory. Case Presentation. An 
81-year-old male patient, with known impaired renal function, presented to our emergency department with a severe enoral bleeding 
aer tooth extraction. e DOAC therapy—indicated by known atrial brillation—was interrupted perioperatively and bridged 
with Low Molecular Weight Heparin (LMWH). e acute bleeding was stopped by local surgery. e factors contributing to the 
bleeding complication were bridging of DOAC treatment, together with prolonged drug action in chronic kidney disease. Conclusion. 
In order to decide whether it is necessary to stop DOAC medication for tooth extraction, it is important to carefully weigh up the 
individual risks of bleeding and thrombosis. If DOAC therapy is interrupted, bridging should be reserved for thromboembolic 
high-risk situations. Particular caution is required in patients with impaired kidney function, due to the risk of accumulation and 
prolonged anticoagulant eect of both DOACs and LMWH.
1. Introduction
Direct oral anticoagulants (DOACs) were introduced in recent 
years and are of increasing importance in everyday clinical 
work, in both emergency departments (EDs) and general prac-
tice [1, 2]. Excessive bleeding is a risk for patients on anticoag-
ulant therapy. Hemorrhage aer tooth extraction is frequent 
with an incidence up to 26% and may range from minor to life 
threatening [3]. Management of DOACs in the perioperative 
setting required the responsible physician to have an under-
standing of DOAC indications, pharmacokinetics, drug-drug 
interactions, and their eects on laboratory assays [4, 5]. More 
than 10% of all patients on DOACs have to interrupt their 
anticoagulant medication before an invasive procedure every 
year [4, 6, 7]. Decisions about the time to stop DOACs preop-
eratively must be based on the half-life of the prescribed 
anticoagulant therapy, the bleeding risk of the invasive proce-
dure, and the bleeding (HAS-BLED score) respectively throm-
bo-embolic (CHADS2 score) risk to the patient [4, 8]. To guide 
the perioperative use of DOACs, a checklist should be available 
which covers all aspects of the planned surgical procedure as 
well as lists the patient-specic characteristics that may increase 
the risks of bleeding or thrombosis [7]. For this purpose, spe-
cic guidance was developed to manage dental patients taking 
anticoagulants or antiplatelet drugs [9]. Historically the appli-
cation of LMWH aer stopping oral anticoagulants was rec-
ommended to avoid a perioperative gap with insu£cient 
anticoagulation [8]. ere is no current literature to support 
the practice of heparin bridging to reduce the perioperative 
risk of thromboembolism at DOAC arrest [7]. On the contrary, 
some studies demonstrated even a higher bleeding risk without 
any reduction in thromboembolic complications in patients 
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taking DOACs or vitamin K antagonists when receiving 
 bridging treatment [10]. DOACs have a shorter elimination 
half-life than most vitamin K antagonists and therefore heparin 
bridging has no clinical benet in patients with a short period 
of perioperative DOAC interruption [7]. In summary, this sug-
gests that peri-operative bridging treatment should be restricted 
to patients with high thromboembolic risk and prolonged 
DOAC arrest (>72–96 hours) [10]. Whereas the cessation of a 
vitamin K antagonist induces an imbalance between pro- and 
anticoagulatory factors, making bridging therapy more impor-
tant, this phenomenon is not present with DOACs. Nevertheless, 
many physicians still continue to bridge patients during inter-
ruption of DOAC therapy [11].
2. Case Presentation
An 81-year-old male patient was admitted from a nursing 
home to our ED because of severe enoral bleeding aer the 
extraction of ve teeth from the right lower and upper jaw, 
performed on the previous day in an outpatient clinic. Due to 
atrial brillation (AF), the patient was under oral anticoagu-
lation with apixaban, 2.5 mg twice daily. His CHADS2 score 
showed two points (age and hypertension), leading to an inter-
mediate stroke risk of 4.0% per year [12]. DOAC medication 
was interrupted ve days before the planned dental surgery. 
Bridging therapy with the subcutaneous injection of 0.8 ml 
nadroparin per day was established two days aer oral anti-
coagulation was interrupted. e last dose of nadroparin was 
administered more than 24 hours before surgery.
e patient had a history of lower gastrointestinal bleeding 
and no co-medication with nonsteroidal or corticosteroidal 
medication. Renal function was moderately impaired (KDIGO 
G2), but no creatinine >200 µmol/l and no history or acute 
evidence of uncontrolled hypertension >160 mmHg were pres-
ent, as requested in the HAS-BLED score. is led to a HAS-
BLED score of 2 (1 point for age >65 years, 1 point for previous 
bleeding), corresponding to a bleeding risk of 4.1% per year 
in a validation study of the HAS-BLED score [13].
In addition to atrial brillation and chronic renal insu£-
ciency, the patient was also known to have severe aortic ste-
nosis, coronary and hypertensive cardiopathy, and Parkinson’s 
syndrome. His daily medications were metoprolol, torasem-
ide, aldactone, atorvastatin, citalopram, levodopamine, 
nasteride, pantoprazole, mesalazine, and apixaban as men-
tioned above.
On admission the patient was hypotonic (initial vital signs: 
blood pressure: 102/67 mmHg, pulse: 60 bpm on beta-block-
ers) and afebrile (36.6°C) with a documented body weight of 
74.8 kg. e clinical examination of heart, lungs, and abdomen 
was normal. Further examination revealed enoral ecchymosis 
of the right cheek and a total of ve extraction sockets in the 
upper and lower jaw. In the mandible, the rst and second 
molars (46, 47) were removed. e oral mucosa in this area 
was swollen and partially adapted to the alveolar bone with 
sutures. Aer initial removal of large blood clots, active bleed-
ing was observed in the region of the extraction sockets 46 
and 47 (Figure 1). Laboratory values on admission revealed a 
haemoglobin of 122 g/L, a platelet count of 249 G/L, and a 
creatinine of 142 µmol/l (eGFR 41 ml/min). Coagulation tests 
and drug levels are displayed in Table 1.
Initial treatment consisted of a °uid bolus and a gauze pack 
soaked with tranexamic acid, with pressure directly over the 
enoral wounds assisted by the patient biting down on the 
gauze. Despite these local measures, bleeding from the extrac-
tion site continued. To ensure sustained haemostasis, local °ap 
surgery was performed by the craniomaxillofacial surgeons. 
Local anesthesia (Articaine 4% with 1 : 100,000 epinephrine) 
was performed vestibular to the alveolar ridge. e tooth 
extraction socket was curetted, all blood clots and debris 
removed and rinsed with saline solution. To support local 
haemostasis, several absorbable gelatin sponges with topical 
thrombin (Spongostan®, Ethicon, Germany) were inserted into 
the bony socket. A vestibular mucoperiosteal °ap was created 
to cover the extraction wound. A long-lasting absorbable 
suture (Vicryl 4-0, Ethicon Inc.) was used to achieve primary 
wound closure (Figure 2). According to our local guidelines, 
no systemic reversal of anticoagulant therapy was performed, 
as the bleeding was controlled by surgical intervention [7].
During surveillance in the ED and the further hospitali-
sation, the patient remained haemodynamically stable. 
Haemoglobin dropped to 84 g/l at 24 hours aer presentation 
and remained stable until discharge to the nursing home 3 days 
aer admission. Oral anticoagulation with apixaban was 
restarted 4 days aer the bleeding event with the same dose.
3. Discussion
e management of spontaneous bleedings under oral anti-
coagulation and the perioperative management of patients 
under DOAC therapy are essential. Specic scores exist to 
assist with assessing the AF-related thromboembolic risk 
(CHADS2 score) in the absence of anticoagulation, and the 
risk of major bleeding (HAS-BLED score) in patients with oral 
anticoagulant treatment [7]. However, the utility of these 
scores has not been prospectively validated in the periopera-
tive setting [7, 14]. Moreover, each operation should be clas-
sied according to the bleeding risk [6]. e bleeding risk of 
tooth extraction is minimal when limited up to three teeth [6]. 
ere is evidence that continuation of DOAC therapy is safe 
for minor dental procedures [15]. When DOAC therapy is 
stopped for surgery, as in the case we present, bridging with 
LMWH is only recommended for patients with a high risk of 
thromboembolism [8].
Figure 1: Oral bleeding aer removal of the rst and second molars.
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In each situation, the risk of bleeding must be weighed 
against the risk of a thromboembolic event. Assessing the risk 
for bleeding under anticoagulation, with a HES-BLED score 
of 2 and a low to moderate procedural bleeding risk, the cumu-
lative bleeding risk for this patient was only moderately ele-
vated. e risk for a thromboembolic event was elevated with 
a CHADS2 score of 2, but with no recent thromboembolism in 
the past 12 months and impaired renal function, stopping apix-
aban prior to the tooth extraction without bridging would have 
been appropriate according to international guidelines [16].
When the thromboembolic risk outweighs the risk of 
bleeding, heparin bridging should be discussed [7]. For 
LMWH, the dose and regimen must be adapted according to 
the patient’s clinical characteristics (e.g., weight and renal 
function) taking into account the risk of bleeding [17]. In con-
trast to subcutaneously administered LMWH, the use of intra-
venous unfractionated heparin (UFH) requires hospitalization 
in order to monitor anticoagulant level, but has the advantage 
of being eliminated independently of the patient’s renal func-
tion [11]. In addition, UFH can be completely antagonized in 
contrast to LMWH [11]. In any case, the decision of periop-
erative management of anticoagulant therapy should be made 
in consultation of the individual patient taking into account 
of all associated circumstances.
e renal function in this patient was impaired and led to 
a persistently elevated anti-Xa level at hospital admission, even 
though the last dose of apixaban was administered >5 days 
previously and the last injection of LMWH >24 hours prior to 
admission. Apixaban is mainly metabolized via CYP3A4 in 
the liver and only partially excreted by the kidneys, making 
apixaban a reasonable choice in patients with limited renal 
function. Nevertheless, the anti-Xa level of this patient was 
elevated, which emphasizes the need for special caution in 
patients with impaired kidney function even for apixaban. Two 
multicenter studies concluded that 48 hours without DOAC 
treatment might not guarantee the absence of residual antico-
agulant eect at the time of intervention in up to 15% of all 
patients [18, 19]. Together with the high inter-individual var-
iability of plasma concentrations, it is now suggested that the 
ideal timing of stopping DOAC treatment is based on plasma 
concentration measurements of DOACs in the periprocedural 
setting, especially for procedures with a high risk of bleeding 
[19, 20].
When acute bleeding occurs, rapid assessment of a patient’s 
anticoagulation level helps to determine the anticoagulant’s 
contribution to the bleeding, the need for a reversal strategy, 
and to assist in planning the time of invasive surgery, if 
required [5]. As the anticoagulant activity of DOACs is directly 
proportional to the plasma concentration, a direct measure-
ment by liquid chromatography/tandem mass spectrometry 
would be the most accurate way to measure drug concentra-
tions [21]. Unfortunately, this technology is not available in 
most acute care settings. e use of prothrombin time (PT) 
and activated partial thromboplastin time (aPTT) assays only 
poorly re°ect the anticoagulant eect of apixaban [21]. For 
this reason, the best measurement for assessing the eect of 
apixaban is a calibrated anti-Xa-activity assay. LMWH is also 
monitored with anti-Xa activity measurements [5]. In our 
patient, post-extraction measurements of drug activity did not 
help to guide therapy, as the anti-Xa-activity assay available 
in our hospital used for the apixaban level is in°uenced by the 
given LMWH and vice versa. ese results of the anti-Xa 
assays could only indicate that anticoagulant activity caused 
by LMWH and/or apixaban was present on admission. 
erefore, especially in emergency medicine with urgent treat-
ment indications, it is important to be aware that interferences 
between LMWH and DOAC activity measurement may gen-
erally lead to elevated drug levels with limited validity for a 
particular medication. Elevated drug levels indicate a haemo-
static derangement in general and incorrect interpretation of 
these results may lead to dangerous patient management. 
Although apixaban was restarted in an unaltered dose at dis-
charge from hospital, close monitoring in this patient was 
recommended to avoid accumulation.
Guidelines for bleeding under anticoagulation are impor-
tant for ED clinicians. A previous study concluded that patients 
under DOACs and phenprocoumon with bleeding events aer 
Table 1: Coagulation tests on emergency department admission.
Activated partial thromboplastin time (aPTT); International normalised ratio (INR); Prothrombin time (PT).
Parameter Norm values On admission
INR 0.7–1.2 1.13
PT (s) 10–12 11.7
aPTT (s) 25–36 37.9
rombin time (s) 15.5–19.4 17.6
Fibrinogen (g/L) 1.75–3.75 3.19
Low molecular weight heparin (LMWH) anti-Xa (AntiXa/mL) 0.6–1.0 (at 4 hours aer injection) 1.02 (at >24 hours aer injection)
Apixaban anti-Xa (ng/mL) No anticoagulant eect <30 64.89
Figure 2: Wound condition aer haemostasis and closure with a 
vestibular mucoperiosteal °ap.
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tooth extraction have a longer length of stay in the ED and more 
frequent surgical intervention than patients without anticoag-
ulant therapy [22]. With the increasing number of diﬀerent 
anticoagulation strategies in recent years, the training of emer-
gency physicians as well as family doctors who prescribe and 
stop DOAC therapy perioperatively and the implementation of 
treatment algorithms have become increasingly important.
erefore, in our institution (ED, Inselspital, University 
Hospital, Bern, Switzerland), a pragmatic treatment algorithm 
for bleeding in combination with anticoagulant treatment has 
been implemented [5].
4. Conclusion
In order to decide whether it is necessary to stop DOAC med-
ication for tooth extraction, it is important to carefully weigh 
up the individual risk of bleeding and of thrombosis. If three 
teeth or fewer are extracted, the continuation of DOAC ther-
apy can be safe. If DOAC therapy is interrupted, bridging 
should be reserved for thromboembolic high-risk situations. 
Particular caution is required in patients with renal insuﬃ-
ciency as it may lead to prolonged anticoagulant eﬀect.
Since bleeding aer tooth extraction is diﬃcult to treat in 
anticoagulated patients, local treatment algorithms are essen-
tial for anticoagulation related bleeding.
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